title: Minimal residual disease (MRD) analysis in the non-MRD-based ALL IC-BFM 2002 protocol for childhood ALL: is it possible to avoid MRD testing?
abstract: The ALL IC-BFM 2002 protocol was created as an alternative to the MRD-based AIEOP-BFM ALL 2000 study, to integrate early response criteria into risk-group stratification in countries not performing routine PCR-based MRD testing. ALL IC stratification comprises the response to prednisone, bone marrow (BM) morphology at days 15 and 33, age, WBC and BCR/ABL or MLL/AF4 presence. Here, we compared this stratification to the MRD-based criteria using MRD evaluation in 163 patients from four ALL IC member countries at days 8, 15 and 33 and week 12. MRD negativity at day 33 was associated with an age of 1-5 years, WBC<20,000 microl(-1), non-T immunophenotype, good prednisone response and non-M3 morphology at day 15. There were no significant associations with gender or hyperdiploidy in the study group, or with TEL/AML1 fusion within BCP-ALL. Patients with M1/2 BM at day 8 tended to be MRD negative at week 12. Patients stratified into the standard-risk group had a better response than intermediate-risk group patients. However, 34% of them were MRD positive at day 33 and/or week 12. Our findings revealed that morphology-based ALL IC risk-group stratification allows the identification of most MRD high-risk patients, but fails to discriminate the MRD low-risk group assigned to therapy reduction.
authors.affiliation: Department of Pediatric Hematology and Oncology, CLIP, Second Medical School, Charles University and University Hospital Motol, Prague, Czech Republic.
authors.forename: E
authors.initials: E
authors.lastname: Fronkova
authors.forename: E
authors.initials: E
authors.lastname: Mejstrikova
authors.forename: S
authors.initials: S
authors.lastname: Avigad
authors.forename: K W
authors.initials: KW
authors.lastname: Chik
authors.forename: L
authors.initials: L
authors.lastname: Castillo
authors.forename: S
authors.initials: S
authors.lastname: Manor
authors.forename: L
authors.initials: L
authors.lastname: Reznickova
authors.forename: T
authors.initials: T
authors.lastname: Valova
authors.forename: K
authors.initials: K
authors.lastname: Zdrahalova
authors.forename: O
authors.initials: O
authors.lastname: Hrusak
authors.forename: Y
authors.initials: Y
authors.lastname: Jabali
authors.forename: M
authors.initials: M
authors.lastname: Schrappe
authors.forename: V
authors.initials: V
authors.lastname: Conter
authors.forename: S
authors.initials: S
authors.lastname: Izraeli
authors.forename: C K
authors.initials: CK
authors.lastname: Li
authors.forename: B
authors.initials: B
authors.lastname: Stark
authors.forename: J
authors.initials: J
authors.lastname: Stary
authors.forename: J
authors.initials: J
authors.lastname: Trka
mesh_terms: D000293:Adolescent; D000367:Age Factors; D048430:Cell Shape; D002648:Child; D002675:Child, Preschool; D006801:Humans; D016130:Immunophenotyping; D007223:Infant; D007958:Leukocyte Count; D018365:Neoplasm, Residual / Q000175:diagnosis*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000175:diagnosis* / Q000628:therapy; D011379:Prognosis; D018570:Risk Assessment; D016896:Treatment Outcome